Phase 3
Completed N=23
Use of N-Acetylcysteine (NAC) in Fingernail Biting
Onychophagia
Source: ClinicalTrials.gov NCT01993849 ↗
Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcomePrimary: Number of Participants Enrolled Within One Year — 12; 11 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
To conduct a pilot randomized placebo-controlled feasibility trial of N-acetylcysteine (NAC) in onychophagia, preliminarily assessing the tolerability and effects of this pharmacotherapy on young adults who bite their fingernails. It is proposed that NAC will help decrease fingernail biting.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Enrolled Within One Year |
12; 11 | — |
Eligibility Criteria
Inclusion Criteria
- 1. Age 18-30 2. Fingernail biter for ≥5 years
Exclusion Criteria
- 1. Any unstable major DSM-IV Axis I psychiatric disorder in the past month (e.g., psychotic disorders, bipolar disorder, major depressive disorder) 2. Current substance dependence in the past month 3. Current unstable major medical disorder or medical condition in the past 6 months (e.g., renal impairment) 4. Current pregnancy or breastfeeding 5. Current seizure disorder or asthma, due to possible elevated risk for adverse effects with NAC in individuals with these conditions 6. Known hypersensitivity to NAC 7. Use of carbamazepine or nitroglycerin (or any other medication deemed to be hazardous if taken with NAC) within 14 days of study participation
Data sourced from ClinicalTrials.gov (NCT01993849). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.